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Introduction
Numerous clinical practice guidelines have been developed at the international, European and national levels to help doctors, other health professionals and patients decide which care is appropriate in different clinical circumstances. Most guidelines are structured like textbooks or encyclopaedia, covering a disease and its aetiology, diagnosis, treatment and prevention in their entirety. While such guidelines have the advantage of being comprehensive, the process of developing and updating them can be expensive and time-consuming. Indeed, an evidence-and consensusbased guideline can take up to three years to develop and can require up to €450 000, excluding the opportunity cost of staff time. [1] [2] [3] Moreover, the length and detail of most clinical practice guidelines can serve as a disincentive to their uptake. Too many recommendations in a guideline make it difficult for health professionals to identify the most important issues and targets. Also, like textbooks, guidelines often cannot answer highly specific questions because the information being sought is either spread across multiple sections or is too granular to have been covered. 4 Another drawback of clinical guidelines in dermatology is the lack of a systematic approach to selecting and prioritizing topics for guideline development. Often such decisions are made based on an implicit judgement process taking criteria such as disease burden or prevalence into account. Systematic approaches that look at guideline users and their needs are rare, [5] [6] [7] but have the potential to improve usability and uptake.
The current project was undertaken in collaboration between the European Academy of Dermatology and Venereology (EADV) and the Division of Evidence-Based Medicine, Charit eUniversit€ atsmedizin Berlin. Its aim was to develop and implement a systematic approach to identify and rank the 'most clinically relevant questions' in everyday practice among dermatologists belonging to a large professional association. In addition to reflecting on the practicability of the survey tool, we discuss the results in terms of the feasibility of developing the resulting guideline suggestions, focusing in particular on the challenges and opportunities of doing so.
Methods
We developed a two-phase online survey using the open source tool LimeSurvey and deployed this among all practicing members of the EADV (n = 6262). The first-phase survey focused on collecting the clinical questions that EADV members felt would benefit most from short, evidence-based guidance. The secondphase survey asked EADV members to rank the resulting list of topics according to their importance. Both phases are described in greater detail below.
Phase 1: Identification of topics
Survey design and participants The first-phase survey questionnaire consisted of an introduction page that described the aim of the survey and provided examples of the questions we aimed to obtain from respondents (Fig. 1) . The page included a drop-down menu with a list of disease categories to help participants structure their thoughts and stimulate ideas (Fig. 2) . No login or password was required. Once participants had selected a category from the drop-down menu, a blank text box appeared along with the request for the participants to enter their question.
After pressing submit, participants were given the option to repeat this process and enter another question or exit the survey. Participants were also invited at this point to provide an email address in case we needed to contact them for further clarification. If no address was provided, participation in the survey was anonymous.
The questionnaire was piloted by two consultants and two specialty registrars at the Department of Dermatology, Venereology and Allergy at Charit e -Universit€ atsmedizin Berlin, who found it to be functional and easy to use. Subsequently, all dermatologist members of the EADV were invited via email on 26 April 2017 to take part in the survey. A reminder was sent on 20 June 2017.
Analysis of results
We exported the results of the first-phase survey into an MS Excel template, retaining the broad disease categories given in the drop-down menu of the survey questionnaire. In each category, we grouped the responses according to specific diseases and also assessed: 1 which intervention was involved (if any); 2 whether the response pertained to treatment or monitoring; 3 whether the response was covered by existing European guidelines (not at all/partially/mostly/well); and 4 whether the response was a suitable candidate for developing guidance (yes/no). The suggestions were subsequently grouped and combined into broader topics to be presented to, and ranked by, the participants in the second-phase survey.
Phase 2: Ranking of topics
Survey design and participants In the second-phase survey, we presented the list of topics derived from the first-phase to all practising members of the EADV by means of another online questionnaire. From this list, participants were asked to choose 10 items they felt would benefit most from short, evidence-based guidance and rank these according to their importance. To do so, participants dragged topics from the column on the left side of their screens and dropped them into the column on the right (Fig. 3) . The interface did not allow participants to submit their results if they had ranked fewer or more than 10 items. The topics in the list were presented in random order to each participant to avoid order effects bias. All practising members of the EADV were invited via email on 25 October 2017 to take part in the second-phase survey. A reminder was sent on 15 November 2017.
Analysis of results Every time a topic was ranked among the top 10 by a participant, we assigned points to it ranging from one (ranked lowest by the participant) to 10 (ranked highest by the participant). We then used the cumulative number of points for each topic to create an overall ranking.
Results

Phase I
Response rates The first-phase survey was open from 26 April 2017 until 4 July 2017. The invitation to participate was sent by the EADV to 6262 recipients, all of whom were dermatologist members of the EADV on the academy's mailing list. Of these emails, 92 were returned as undeliverable for various reasons. Of the remaining 6170 recipients, approximately 2391 (38.8%) opened the email at least once and approximately 726 (11.7%) clicked on the embedded link to our survey questionnaire at least once. These open and click statistics derive from tracking reports provided by the EADV from the MailChimp© commercial marketing automation platform and represent rough estimates only.
In total, 229 responses were received in this phase. Because participants were allowed to submit multiple responses or may have forwarded the invitation to colleagues, we were unable to calculate an exact response rate, although this clearly could not have been higher than 3.7% (229/6170). Some of the 229 responses received contained more than one question, comment or topic each. For the purpose of analysis, we separated these into individual items, leading to 265 items in total.
Responses Over 40% (n = 115) of the responses unexpectedly comprised short, disease-oriented, textbook-like general topics such as 'Lichen planus', 'Vitiligo therapies' or 'How to treat disease X' rather than specific questions. As a result, we grouped all responses according to themes and subsequently combined these, where appropriate, into a list of 35 broader topics for ranking in the second-phase survey (Box 1).
The largest number of suggestions was received for the category 'Infectious disease of the skin, including STDs' (n = 56), followed by 'Other topics' (n = 30), 'Papulosquamous and eczematous diseases' (n = 25) and 'Pigmentary disorders' (n = 24) and 'Medical treatments' (n = 24).
Many suggestions (n = 112) were related to topics already covered at least partially in existing European guidelines. Among all 265 suggestions made, such guidelines covered the related topics well in 64 (24.2%) cases, mostly in 15 (5.7%) cases, partially in 33 (12.5%) cases and not at all in 112 (42.3%) cases. Suggestions that were well or mostly covered by existing guidelines were excluded from further analysis and hence from the ranking exercise undertaken by EADV members in our secondphase survey. Lastly, 41 (15.5%) suggestions were either not specific enough for a judgement to be made in this regard or the researchers were unable to find the relevant information.
Phase II
Response rates The second-phase survey was open from 25 October 2017 until 23 November 2017. As with the first invitation, the invitation to participate in the second-phase survey was sent to 6262 recipients and resulted in 92 emails returned as undeliverable. Of the remaining 6170 recipients, approximately 2427 (39.3%) opened the email at least once, and approximately 730 (11.8%) clicked on the embedded link to the survey questionnaire at least once. A total of 602 recipients (9.6%) Prioritizing topics in guideline development participated in second-phase survey and ranked their top 10 topics. A further 16 recipients started to rank topics but did not finish doing so.
Responses Participants ranked 'Systemic drug treatment in dermatology during pregnancy and for women wishing to have children in the near future' as the topic they felt would most benefit from short, evidence-based guidance, followed by 'Alopecia areata' and 'Connective tissue diseases, interpretation of lab results (e.g. antibodies)'. Table 1 shows the topics ranked in the top 10 according to total weighted points. It also shows, for comparison, the total number of times each topic was ranked at any place within the top 10. This alternative method of ranking resulted in the same list of 10 topics, with only slight differences in order after second place. For the full list of ranked topics, see Appendix A.
Discussion
The aim of our study was to develop and implement a systematic approach to identify and rank the questions in everyday practice that dermatologist members of the EADV felt would benefit most from short, evidence-based guidance. While the response rate in our first-phase survey could not be reliably calculated, the open and click statistics for the first invitation email and the relatively small number of suggestions submitted by members suggest that it was low and not higher than 3.7%. Response rates like this are not unusual for electronic surveys of members of professional dermatological societies, such as the British Association of Dermatologists, 8, 9 but they are by no means the rule, with some achieving rates greater than 30%.
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The response rate for our second-phase survey was almost 10%, an improvement that may be attributable to the brevity of the invitation email for this phase and the simple, almost gamelike nature of the drag-and-drop ranking task. A limitation of our study is that we did not collect sociodemographic or other data on our respondents, so we are unable to say whether the 602 individuals who took part in our second-phase survey were broadly representative of dermatologists in Europe in terms of age, country, gender, professional experience or other relevant characteristics. One of our goals, however, was to keep the questionnaires as short as possible knowing that response rates to electronic surveys are generally very low.
Although we had asked members to submit specific questions and provided several examples of these, we received a large number of suggestions that were disease-oriented and not phrased as questions or in a specific manner. Potential reasons for this include participants' pre-existing expectations of what guidelines should look like and how they should be structured; busy schedules that prevented participants from reading the survey text thoroughly or entering the questions as specified; or our use of a free-text box to collect data. Despite the format of the suggestions, we were able to analyse and compile them into a list of topics in need of guidance, and participants were able to rank these according to their importance with ease. Indeed, the great majority (over 80%) of those who clicked on the link in our invitation to the second-phase survey completed the ranking exercise in its entirety. Being anonymous, our survey approach was able to avoid situations in which more dominant respondents might have been able to influence the outcome of the ranking procedure. In that sense, and in its two-phase structure, it resembles to some degree a more formal Delphi exercise, but without the added time and expense of additional feedback rounds.
The topic ranked highest by EADV members -'Systemic drug treatment in dermatology during pregnancy and for women wishing to have children in the near future' -poses an interdisciplinary challenge. While the topic is partially covered for psoriasis in the 2017 update of the eponymous European evidenceand consensus-based (S3) guideline, 13 there is at present no guideline that focuses solely on systemic treatments relevant to dermatology in this population. This is unfortunate given evidence suggesting that the use of prescription and over-the-counter medication in pregnancy is widespread and increasing. 14,15 A guideline dedicated to summarizing and synthesizing the limited and often disparate evidence in this area could be a valuable addition to the current portfolio, particularly if developed by an interdisciplinary team. The second-place ranking of the topic 'alopecia areata' is likely due to the paucity of effective treatment options and the growing number of case reports of new treatments (particularly of an off-label nature) juxtaposed with increased expectations of patients resulting in part from their own information gathering. Moreover, alopecia areata is a relatively common disease, with a lifetime risk of 1.7% and a prevalence estimated between 0.1% and 0.2% worldwide. 16 According to the 2010 Global Burden of Disease study, it accounted for 1.35 million global disabilityadjusted life years (DALYs) -more than the 1.06 million DALYs attributable to psoriasis. 17 Given these points and the fact that the most recent guidance on this topic is from 2012, 18 developing a European guideline in this area would be of value. The guideline would most likely need to be primarily consensus based in view of the limited evidence available from randomized controlled trials. The third topic, 'connective tissue diseases, interpretation of lab results (e.g. antibodies)', is more in line with our original idea of specific 'burning questions' for which guidance is needed. A concise explanation of measures such as sensitivity, specificity and positive and negative predictive values combined with evidence-based explanations of how best to interpret laboratory results in connective tissue disease may be a suitable focus for future or existing guidelines in this topic area.
Overall, our prioritization exercise yielded several interesting narrower topics that might often be missed or buried in the detail of traditional disease-based guidelines. Beyond the systemic drugs in pregnancy and connective tissue diseases mentioned above, these included hyperpigmentation and the use of systemic corticosteroids. With so many country-specific guidelines covering the same topics and often making conflicting recommendations, it may be that overarching European guidelines joining up the resources of different guideline development groups or organizations can focus on more niche and needed topics such as these to make better use of scarce resources.
A large number of suggestions involved topics already covered in existing European guidelines. Past research has pointed to high awareness among European dermatologists of clinical practice guidelines, 19 such as the European S3 guideline on the systemic treatment of psoriasis vulgaris or the German S3 guideline on the management of anticoagulation in cutaneous surgery. 20 However, our finding suggests that the dissemination of guidelines may nevertheless need to be improved among EADV members and others. It also underscores the importance of evaluating the dissemination and implementation of guidelines after they have been launched, focusing in particular on metrics such as awareness, familiarity and adherence. 21 Before final decisions are made about which of the top 10 topics are to be developed as guidelines or be the focus of guideline updates, it will be important to set out and then apply further explicit criteria to the selection process. In addition to assessing the feasibility of a systematic search for each topic, we suggest taking account of the following factors identified by Carter et al. 22 as being important or very important for setting priorities for clinical practice guideline activities: 1 Health burden on the population 2 Economic burden of disease on society 3 Cost of treatment to the health care system 4 Extent of variation in practice 5 State of scientific knowledge 6 Cost of guideline development Doing so will ensure that priority setting is transparent and not based solely on the judgement of a sample of stakeholders. 5 Along these lines, guideline developers should strive to involve all relevant stakeholders, including academic and office-based dermatologists, general practitioners and patients to ensure the practicability of the resulting guidelines.
Conclusions
Our two-phase survey of EADV members and a structured ranking process was practical to implement, yielding a list of the top 10 topics in dermatology and venereology that participants felt were most in need of short, evidence-based guidance. The first three of these were 'Systemic drug treatment in dermatology in pregnancy and for women wishing to have children in the near future', 'alopecia areata' and 'connective tissue diseases, interpretation of lab results (e.g. antibodies)'. A large number of suggestions received in the first phase of the survey involved topics already covered in existing European guidelines, pointing to a need to improve efforts at guideline dissemination and to evaluate the dissemination and implementation of guidelines after they have been launched.
